Bahrain approves Chinese Covid vaccine for use

&Tab;&Tab;<div class&equals;"wpcnt">&NewLine;&Tab;&Tab;&Tab;<div class&equals;"wpa">&NewLine;&Tab;&Tab;&Tab;&Tab;<span class&equals;"wpa-about">Advertisements<&sol;span>&NewLine;&Tab;&Tab;&Tab;&Tab;<div class&equals;"u top&lowbar;amp">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;<amp-ad width&equals;"300" height&equals;"265"&NewLine;&Tab;&Tab; type&equals;"pubmine"&NewLine;&Tab;&Tab; data-siteid&equals;"111265417"&NewLine;&Tab;&Tab; data-section&equals;"1">&NewLine;&Tab;&Tab;<&sol;amp-ad>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;<&sol;div><p>Bahrain said on Sunday that it has approved the use of a Chinese coronavirus vaccine&comma; following its earlier approval of a vaccine made by Pfizer and its German partner BioNTech&period;<&sol;p>&NewLine;<p>Bahrain’s state-run news agency said the Sinopharm vaccine will be made available in the island kingdom off the coast of Saudi Arabia in the Persian Gulf&period;<&sol;p>&NewLine;<p>However&comma; it offered few details on study results of the vaccine&comma; in line with the United Arab Emirates&comma; which last week announced that the vaccine is 86&percnt; effective&period;<&sol;p>&NewLine;<p>The Emirati statement provided few details but marked the first public release of information on the efficacy of the jab&period;<&sol;p>&NewLine;<p>Bahrain said more than 7&comma;700 people had signed up to take part in a trial of the Sinopharm&period;<&sol;p>&NewLine;<p>The kingdom earlier said it plans to give the public the vaccine free of charge&comma; but has yet to answer any questions about its programme&period;<&sol;p>&NewLine;<p><&excl;--Ads1--><&sol;p>&NewLine;<p>The Sinopharm vaccine has been approved for emergency use in a few countries and the company is still carrying out late-stage clinical trials in 10 countries&period;<&sol;p>&NewLine;<p>Morocco is gearing up for an ambitious Covid-19 vaccination programme&comma; aiming to vaccinate 80&percnt; of its adults in an operation starting this month that is relying initially on the Sinopharm vaccine&period;<&sol;p>&NewLine;<p>Sinopharm’s jab relies on a tested technology&comma; using a killed virus to deliver the vaccine&comma; similar to how polio immunisations are made&period;<&sol;p>&NewLine;<p>Leading Western competitors&comma; like the vaccine made by Pfizer and its German partner BioNTech&comma; use newer&comma; less-proven technology to target the coronavirus’s spike protein using RNA&period;<&sol;p>&NewLine;<p>The UK has already begun vaccinating people with the Pfizer jab and the US is poised to follow&period;<&sol;p>&NewLine;<p>Pfizer has reported its vaccine as being 95&percnt; effective&comma; while another RNA candidate from Moderna appears to be 94&period;5&percnt; effective&period;<&sol;p>&NewLine;<p><&excl;--Ads2--><&sol;p>&NewLine;<p>Results suggest a third vaccine from Oxford University and AstraZeneca is safe and about 70&percnt; effective&comma; but questions remain about how well it may help protect those over 55&period;<&sol;p>&NewLine;<p>Also on Sunday&comma; Kuwait’s state-run Kuna news agency announced that the oil-rich country’s health ministry has given the go-ahead for emergency use of the Pfizer vaccine&period;<&sol;p>&NewLine;<p>The ministry had already offered citizens the option to pre-register on its website to receive the vaccine&period;<&sol;p>&NewLine;&Tab;&Tab;&Tab;<div style&equals;"padding-bottom&colon;15px&semi;" class&equals;"wordads-tag" data-slot-type&equals;"belowpost">&NewLine;&Tab;&Tab;&Tab;&Tab;<div id&equals;"atatags-dynamic-belowpost-68ed4eef2a8a1">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<script type&equals;"text&sol;javascript">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback &equals; function &lpar;&rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; false &equals;&equals;&equals; &lpar; window&period;isWatlV1 &quest;&quest; false &rpar; &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&sol;&sol; Use Aditude scripts&period;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings &equals; window&period;tudeMappings &vert;&vert; &lbrack;&rsqb;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings&period;push&lpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;divId&colon; 'atatags-dynamic-belowpost-68ed4eef2a8a1'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;format&colon; 'belowpost'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; document&period;readyState &equals;&equals;&equals; 'loading' &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;document&period;addEventListener&lpar; 'DOMContentLoaded'&comma; window&period;getAdSnippetCallback &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; else &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback&lpar;&rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<&sol;script>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>


Discover more from London Glossy Post

Subscribe to get the latest posts sent to your email.

- Advertisement -
Exit mobile version